Neurotech Newsletter #18
Published on November 21, 2025
Executive Summary
Welcome to the 18th edition of the Carter Sciences Neurotech Newsletter!
This edition pulses with momentum in neurotechnology, from over $500 million in funding fueling AI-driven brain diagnostics and wearable EEG innovations to a wave of FDA clearances accelerating non-invasive therapies for chronic pain, adolescent depression, and spinal cord recovery. Clinical breakthroughs reveal adenosine's role in rapid antidepressants and EEG's potential for amyloid detection in Alzheimer's, while strategic partnerships between giants like Philips and Microsoft propel AI-enhanced neuroimaging and BCIs toward real-world impact. Leadership shifts at key players like Cala Health and ONWARD Medical signal a commercialization surge, blending neuromodulation with precision medicine to redefine neurological care.
Check out the highlights below and as always send through any recommendations or feedback to chay@cartersciences.com
Funding News
NervGen Pharma Announces US$10 Million Private Placement
Nasdaq | 2025-11-18
NervGen Pharma Corp., a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurologic disorders, announced a non-brokered private placement of units to institutional and accredited investors, aiming to raise US$10 million to support its development pipeline.
Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health
Beacon Biosignals | 2025-11-13
Beacon Biosignals, a neurotechnology firm specializing in AI-driven diagnostics and precision medicines for brain health, secured an oversubscribed $86 million Series B funding round led by investors including Innoviva, Google Ventures, and Nexus NeuroTech Ventures, to expand the world's largest neurodiagnostic dataset and advance AI biomarkers for clinical use.
Nyxoah raises $77M to support Genio sleep apnea neuromod rollout
MassDevice | 2025-11-13
Nyxoah, a Belgium-based neuromodulation company, closed financings totaling up to $77 million, including a $25 million private placement of 5.5 million shares at $4.63 each and a convertible bond of up to $52 million, to fund the commercial rollout of its Genio hypoglossal nerve stimulation system for obstructive sleep apnea.
Axoft Awarded $835,000 for MEMS Cleanroom Development
LinkedIn | 2025-11-12
Axoft, a neurotechnology company developing soft brain implants, received $835,000 in non-dilutive funding from the Massachusetts Manufacturing Innovation Initiative to establish an in-house MEMS cleanroom at its Cambridge headquarters on the MIT campus, enabling scaled production of its proprietary Fleuron materials for medical devices.
Cochlear-backed Epiminder prepares for $325m ASX listing
Australian Financial Review | 2025-11-11
Epiminder, a Melbourne-based biotech supported by Cochlear, is set to list on the ASX with a $325 million market capitalization, planning to raise $125 million at $1.50 per share following FDA approval of its Minder electrode implant for epilepsy treatment, which sits under the scalp to detect and respond to seizures.
NextSense Raises $16 Million Series A for Wireless EEG Earbuds
BusinessWire | 2025-11-11
NextSense, a pioneer in wearable EEG technology, closed an oversubscribed $16 million Series A led by Ascension Ventures with participation from Satori Neuro, Corundum Neuroscience Fund, and notable individuals like neuroscientist David Eagleman, to launch the first truly wireless earbuds with integrated EEG sensors for brain monitoring.
Band of Angels Invests in Theta Neurotech's Seizure Prediction Interface
LinkedIn | 2025-11-10
The Band of Angels invested in Theta Neurotech, which developed a patented brain-computer interface to predict and alert epilepsy patients of impending seizures, enabling proactive treatment and improving patient outcomes through early intervention.
Smartlens raises $5.2 million to advance miLens FDA clearance and launch
Eyes On Eyecare | 2025-10-29
Smartlens, a clinical-stage ophthalmic technology company, raised over $5.2 million in an oversubscribed bridge round to advance FDA clearance and launch of its miLens, a contact lens-based system for glaucoma monitoring, alongside its AI-powered Slit IQ remote examination platform.
Industry Analysis
These funding rounds, totaling over $200 million across neuroreparative therapies, AI-driven brain diagnostics, neuromodulation devices, and wearable EEG tech, signal robust investor confidence in neurotechnology's commercial potential, potentially accelerating innovation in treating neurological disorders like epilepsy, sleep apnea, and spinal cord injuries while expanding manufacturing and market access in key hubs like Boston and Melbourne. This influx could drive consolidation among startups, heighten competition for talent, and attract more venture capital to bridge preclinical and clinical stages, ultimately lowering barriers to personalized neurotherapeutics in the wider healthcare market.
Trend Conclusion
A clear trend emerges of surging investments in implantable and wearable neurodevices for epilepsy and brain health monitoring, with AI integration and non-invasive options like wireless EEG earbuds gaining traction alongside traditional neuromodulation, reflecting a shift toward predictive, patient-centric solutions that prioritize scalability and regulatory milestones to address unmet needs in chronic neurologic conditions.
Regulatory & Reimbursement News
Spryte Medical Secures FDA IDE for INSYTE Aneurysm Trial
LinkedIn | 2025-11-20
Spryte Medical has obtained FDA Investigational Device Exemption (IDE) approval to launch the INSYTE pivotal clinical trial, evaluating the safety and effectiveness of its neuro Optical Coherence Tomography (nOCT) imaging system for use during intracranial aneurysm treatment procedures, marking a key advancement in neurointerventional imaging technologies.
Paradromics Receives FDA Approval for Connect-One Study
Paradromics | 2025-11-20
Paradromics has secured FDA Investigational Device Exemption (IDE) approval for its Connect-One clinical study, assessing the long-term safety and efficacy of the Connexus Brain-Computer Interface (BCI) in restoring speech and enabling computer control for individuals with severe motor impairments due to neurological conditions.
QuantalX Neuroscience Gains FDA De Novo Clearance for Delphi-MD™ Device
LinkedIn | 2025-11-18
QuantalX Neuroscience has received FDA De Novo clearance for its Delphi-MD Functional Neuro-Imaging (FNI) device, introducing a novel modality for rapid assessment of brain function by benchmarking patient data against a normative database, thereby supporting personalized neurological evaluations in diverse clinical settings.
ONWARD Medical Secures FDA Clearance for ARC-EX Home Use
LinkedIn | 2025-11-17
ONWARD Medical has gained FDA clearance to expand the indication for its ARC-EX System, permitting home use of the non-invasive transcutaneous electrical spinal cord stimulation device by adults with spinal cord injury to enhance hand strength and sensation through take-home exercises alongside clinic-based functional task practice.
FDA Clears Magstim for Chronic Pain Treatment
Pain Medicine News | 2025-11-14
The FDA has cleared Magstim's Rapid magnetic stimulation device for treating chronic pain by modulating neural pathways involved in pain perception, offering clinicians a non-invasive option to reduce pain intensity, improve physical function, and enhance patient quality of life.
GlobeNewswire | 2025-11-13
BrainsWay has obtained FDA clearance for a label expansion of its Deep Transcranial Magnetic Stimulation (Deep TMS) system, approving its use as an adjunct therapy for major depressive disorder in adolescents aged 15 to 21, broadening access to non-invasive neurostimulation for younger mental health patients.
Augmedics Gains FDA Clearance for AR Headset X2
LinkedIn | 2025-11-12
Augmedics has received FDA 510(k) clearance for its X2 augmented reality headset, featuring an improved form factor and power-efficient design to advance surgical navigation in spine procedures, with the device set to debut at the North American Spine Society annual meeting.
FDA Clears Precisis GmbH for US Epilepsy Study Launch
LinkedIn | 2025-11-10
Precisis GmbH has been granted FDA approval to initiate a U.S. clinical study for its neurotechnology platform targeting drug-resistant epilepsy, representing a pivotal step in developing advanced therapeutic options for epilepsy patients.
Imeka's ANDI 2.0 Gains FDA 510(k) Clearance
LinkedIn | 2025-11-10
Imeka has secured FDA 510(k) clearance for its ANDI 2.0 neuroimaging system, which integrates volumetric and microstructural brain analysis into a unified report to streamline clinical workflows and enhance insights into brain connectivity via quantitative MRI.
Regulatory Impact Analysis
These recent FDA clearances and IDE approvals across neurostimulation, brain-computer interfaces, imaging, and surgical navigation devices signal accelerated market entry for innovative neurotechnologies, potentially lowering barriers for clinical adoption and expanding treatment options for conditions like spinal cord injury, epilepsy, depression, and chronic pain, while fostering competition and investment in the sector.
Regulatory Trend Conclusion
A clear trend emerges of FDA prioritizing non-invasive and minimally invasive neurotech solutions, with multiple De Novo and 510(k) clearances for stimulation and imaging tools alongside IDEs for high-potential BCIs and aneurysm treatments, indicating a regulatory shift toward supporting personalized, home-based, and adolescent-applicable therapies to address unmet needs in neurological and mental health care.
Clinical News
Emteq Labs Publishes Studies Validating OCOsense Smart Glasses
Emteq Labs | 2025-11-20
Emteq Labs has released two peer-reviewed studies validating the accuracy of its OCOsense smart-glasses platform in detecting chewing and meal events, led by Rhiannon Armitage and Dr. Aishwarya P. The first study, conducted under controlled laboratory conditions, demonstrates close alignment with human-coded benchmarks across diverse food textures, highlighting the platform's potential as a Technological Innovation for monitoring human behavior in healthtech applications related to neurotechnology and sensory processing.
VA Study Confirms TMS Protocols Reduce PTSD Symptoms Effectively
Brain Stimulation Journal | 2025-11-13
A large-scale, real-world study involving 756 patients by the U.S. Department of Veterans Affairs evaluates multiple Transcranial Magnetic Stimulation (TMS) protocols for posttraumatic stress disorder (PTSD), including 10Hz, intermittent theta burst stimulation (iTBS), and deep TMS (dTMS). Published in pre-proof status, the research—a multisite cohort study—shows all protocols yielding approximately 20-point reductions on the PTSD Checklist, confirming their clinical efficacy as a non-invasive neuromodulation intervention for treatment-resistant PTSD symptoms.
Adenosine signalling drives antidepressant actions of ketamine and ECT
Nature | 2025-11-05
This preclinical study using mouse models elucidates the mechanism behind the rapid antidepressant effects of ketamine and electroconvulsive therapy (ECT) in treatment-resistant depression, identifying adenosine signaling as a central pathway. The research reveals how these interventions modulate adenosine to achieve swift remission, providing foundational insights into refining therapeutic precision for mood disorders through targeted neurochemical interventions.
Lungpacer Medical Starts AeroNova System Clinical Trial Enrollment
Lungpacer Medical | 2025-11-05
Lungpacer Medical has initiated enrollment in a prospective, open-label, multi-center, randomized controlled clinical trial for its AeroNova system, starting with six patients. The trial assesses the system's sustained temporary transvenous diaphragm neurostimulation—combined with standard care—against standard care alone in reducing multi-organ injury for mechanically ventilated patients, marking an early-phase evaluation of this neurostimulation device for critical care applications.
Breakthrough: Brain-Amyloid Imaging via EEG
Medium | 2025-11-05
A novel Technological Innovation combines conventional EEG with an AI-driven approach to enable brain-amyloid imaging, achieving unprecedented single-subject visualization comparable to amyloid-PET scans. Developed by James Hamet, this breakthrough transforms EEG from a basic electrophysiological tool into a non-invasive imaging modality for detecting amyloid plaques, offering potential advancements in early diagnosis of neurodegenerative conditions like Alzheimer's through accessible neurotechnology.
Clinical Impact Analysis
These clinical developments in neurotechnology underscore a transformative shift toward non-invasive and targeted interventions, enhancing patient care by expanding options for PTSD management via TMS, improving critical care outcomes with diaphragm neurostimulation, and enabling earlier detection of neurodegenerative markers through AI-enhanced EEG. In the broader industry, they signal accelerated adoption of neuromodulation devices and mechanistic insights into rapid antidepressants, potentially reducing treatment resistance and healthcare costs while fostering personalized therapies that integrate wearables and imaging for real-time monitoring and precision medicine.
Research Trend Conclusion
Emerging trends across these articles highlight a convergence of neuromodulation techniques—from TMS and ECT to diaphragm stimulation—and molecular pathways like adenosine signaling, alongside AI-augmented non-invasive diagnostics such as EEG-based amyloid imaging. This points to a growing emphasis on multimodal, mechanism-driven neurotechnologies that bridge preclinical insights with clinical applications, prioritizing rapid, accessible interventions for psychiatric and neurological disorders to address unmet needs in treatment-resistant conditions and critical care.
Commercial Collaborations and Launches
Early Entrepreneurs Program Announced and Applications Open
Neurotech Harbor | 2025-11-21
Neurotech Harbor has launched its second annual Early Entrepreneurs Program, rebranded to support novice innovators in neurotechnology, offering three months of entrepreneurial training and mentorship to individuals from academic, medical, or startup backgrounds with early-stage ideas, aiming to lower commercialization barriers and foster neurotech innovation.
Attune Neurosciences Launches 'Fus Forward' Podcast
LinkedIn (Attune Neurosciences) | 2025-11-21
Attune Neurosciences, through co-founder Keith Murphy and collaborator Charles Caskey, has introduced the 'Fus Forward' podcast focused on focused ultrasound neuromodulation, addressing a gap in dedicated neurotech resources by covering trends, key works, and interviews with experts to advance neuroscience innovations and community engagement.
Avatar Medical and Barco Introduce Eonis Vision 3D Imaging
LinkedIn (Avatar Medical) | 2025-11-20
In a strategic partnership, Avatar Medical and Barco have launched Eonis Vision, an exam-room 3D imaging solution that combines Avatar's 3D visualization software with Barco's glasses-free autostereoscopic display to transform CT and MRI scans into interactive anatomical models, targeting enhanced physician-patient communication for complex neurological conditions without requiring headsets.
Philips and Cortechs.ai extend partnership for neuroimaging
Philips | 2025-11-19
Royal Philips and Cortechs.ai have extended their strategic partnership to integrate Cortechs.ai's AI-enabled quantitative neuroimaging analytics into Philips' MR systems, focusing on delivering faster, objective, and reproducible brain health insights to advance precision diagnostics in neurology and strengthen Philips' market leadership.
Humanity Neurotech Rebrands to Fareon
LinkedIn (Fareon) | 2025-11-17
Humanity Neurotech has rebranded to Fareon, marking a new phase in its mission-driven development with an expanded vision for neurotechnology, signaling upcoming updates to support its commercialization efforts and continued innovation in the sector.
WVU Rockefeller Neuroscience Institute and Cognito Therapeutics Launch Brain Health Collaboratory
Business Wire | 2025-11-13
The West Virginia University Rockefeller Neuroscience Institute and Cognito Therapeutics have launched the Brain Health Collaboratory, a pioneering model integrating clinical care, AI-driven research, and data generation to accelerate non-drug neurotherapies for neurodegenerative diseases and cognitive decline, establishing a learning healthcare ecosystem for real-world validation.
Sense Neuro Moves HQ While Seeking ISO Certification
Cincinnati Business Courier | 2025-11-12
Sense Neuro, a brain scanner startup, has relocated to a larger 10,000-square-foot headquarters in West Chester, Ohio, to support its growth while pursuing ISO certification essential for U.S. manufacturing of its neurotech device, positioning the company for expanded commercialization and regulatory compliance.
GrayMatters Health Launches Prism360 for Psychiatry Clinics
PR Newswire | 2025-11-10
GrayMatters Health has launched Prism360, a comprehensive solution to support psychiatry clinics adopting its Prism brain biomarker platform for PTSD and depression, providing financing, coverage, and operational tools to drive patient access and expand personal objective psychiatry programs across the U.S.
InBrain, Microsoft team up on AI for neurology, BCI tech
MassDevice | 2025-11-10
InBrain Neuroelectronics and Microsoft have formed a strategic collaboration to leverage Microsoft's cloud infrastructure and agentic AI for advancing real-time precision neurology and brain-computer interface therapeutics, utilizing InBrain's graphene-based cortical interfaces to pioneer next-generation neurotech applications.
Oxford Researchers Launch £11M Chronic Pain Programme
Cherwell | 2025-11-08
University of Oxford researchers have initiated the £11 million EPIONE programme, funded by the Engineering and Physical Sciences Research Council, to develop brain implants and neural engineering solutions for chronic pain affecting 28 million in the UK, uniting experts in a six-year effort to create intelligent therapies for improved pain management.
Market Impact Analysis
These commercial developments in neurotechnology, including partnerships like Philips-Cortechs.ai and InBrain-Microsoft, alongside product launches such as Eonis Vision and Prism360, are intensifying market competition by accelerating AI integration and precision tools, enabling faster innovation cycles and broader adoption in neurology and psychiatry, while infrastructure expansions like Sense Neuro's HQ move signal scaling strategies that could drive industry growth through enhanced accessibility and regulatory readiness.
Commercial Trend Conclusion
A clear trend emerges in neurotech toward AI-enhanced collaborations and launches, with multiple initiatives focusing on non-invasive imaging, biomarkers, and neurotherapies to address unmet needs in brain health and chronic conditions, alongside support programs like the Early Entrepreneurs initiative that bolster early-stage commercialization, indicating a maturing ecosystem prioritizing scalable, real-world applications over isolated R&D.
Leadership Appointments
Cala Health Expands Leadership Team for Tremor Therapy Adoption
PRNewswire | 2025-11-18
Cala Health, a leader in bioelectronic medicine, has bolstered its executive team amid accelerating U.S. adoption of its Cala TAPS Therapy for tremor treatment, appointing Kevin Strange as CFO with seasoned finance expertise, Julie Reese as VP of Sales and Therapy Success, Alex Kent as VP of Research, and additional executives to drive commercialization and innovation in neurostimulation therapies.
MicroTransponder Appoints Mead as Board Chair, Adds Lucchese
LinkedIn | 2025-11-17
MicroTransponder, focused on stroke recovery solutions, has strengthened its governance by appointing Dana G. Mead, Jr. as Board Chair and Cynthia Lucchese as an independent director, leveraging their extensive industry and oversight experience to support scaling U.S. commercialization of Vivistim Paired VNS therapy and establishing it as a standard in neurorehabilitation.
Cumulus Neuroscience Appoints Toshio Kimura as Clinical Operations Lead
LinkedIn | 2025-11-14
Cumulus Neuroscience has named Toshio Kimura as Clinical Operations Lead, drawing on his 13-plus years in clinical operations to enhance support for Japanese partners and advance digital biomarker platforms in neuroscience, positioning the company for expanded global clinical trial efficiency in brain health assessments.
Motif Neurotech Appoints Catherine Lapp as Director of Clinical Affairs
LinkedIn | 2025-11-11
Motif Neurotech has appointed Catherine Lapp as Director of Clinical Affairs, bringing her decade-long experience from Nexstim in neuroscience, including leading Phase III trials for targeted TMS and building KOL networks, to accelerate clinical development and commercialization of non-invasive neurostimulation technologies.
Ahmet Tezel Appointed to Cadence Neuroscience Board
LinkedIn | 2025-11-10
Ahmet Tezel, PhD, and Chief Innovation Officer, has joined the board of directors at Cadence Neuroscience, infusing his innovation expertise to guide strategic advancements in the company's neurotechnology portfolio, enhancing its focus on novel therapeutic solutions for neurological disorders.
Gagan Sooch Joins CoMind as Director of Clinical
LinkedIn | 2025-11-10
Gagan Sooch, with 13 years at Insightec leading clinical programs to FDA approval, has joined CoMind as Director of Clinical to advance non-invasive brain monitoring technologies, emphasizing evidence-based innovation to improve brain health assessment and patient outcomes in medtech.
Ken Johnson Joins Meta's Health and Wellness Team
LinkedIn | 2025-11-08
Ken Johnson, PhD in Biomedical Engineering and expert in machine learning and imaging, has joined Meta as a Software Engineer on the Health and Wellness team within Reality Labs and Wearables, contributing to innovative neurotechnology projects that integrate AI with wearables for enhanced health monitoring.
Austin Bodine Appointed Sales Director at Sens.ai
LinkedIn | 2025-11-07
Austin Bodine, formerly with Neuronic, has been appointed Sales Director at Sens.ai, leveraging his neurotechnology background in brain health and human performance to drive sales of personalized neurotech solutions, supporting the company's mission in science, wellness, and self-growth applications.
Sean Sciara Named Chief Commercial Officer at ONWARD Medical
LinkedIn | 2025-11-05
ONWARD Medical has appointed Sean Sciara as Chief Commercial Officer following key milestones like first U.S. sales of its transcutaneous spinal cord stimulation system, IDE approval for implantable neurostimulation, and CE mark, positioning the company to expand commercial efforts in spinal cord injury therapies.
Leadership Impact Analysis
These leadership appointments across neurotechnology firms underscore a strategic push toward commercialization and clinical scaling, potentially accelerating market entry for therapies in tremor treatment, stroke recovery, and brain health monitoring, while fostering innovation through tech giants like Meta, thereby intensifying competition and investment in non-invasive neurostimulation and digital biomarkers to reshape treatment paradigms and improve patient access.
Executive Trend Conclusion
A clear trend emerges in hiring seasoned clinical and commercial experts from established medtech players, alongside board enhancements with innovation leaders, signaling a maturing neurotechnology sector focused on regulatory navigation, global expansion—particularly in Asia—and integration of AI-driven wearables, which could drive consolidation and faster adoption of personalized neurological interventions.
Closing Thoughts
Key Strategic Insights
This edition's neurotechnology landscape reveals a robust ecosystem fueled by over $500 million in funding for AI-driven diagnostics, neuromodulation devices, and wearable interfaces, alongside accelerated FDA clearances for non-invasive tools like BCIs, TMS, and neuroimaging systems, collectively underscoring investor and regulatory confidence in scalable solutions for epilepsy, spinal injuries, and mental health disorders; the "so what" is a maturing market where AI integration and personalized therapies are de-risking clinical translation, enabling companies to capture first-mover advantages in a sector projected to exceed $20 billion by 2030, while leadership hires from medtech veterans signal proactive scaling to bridge R&D and revenue.
Cross-Functional Analysis
Funding surges in startups like Beacon Biosignals and Nyxoah dovetail with regulatory wins for Paradromics' BCI and ONWARD's home-use stimulator, amplifying clinical validations such as TMS for PTSD and EEG-based amyloid detection, which in turn bolster commercial moves like Philips-Cortechs.ai's AI neuroimaging partnership and GrayMatters' Prism360 launch; this interplay highlights cross-silo synergies where early-stage capital supports IDE trials, clinical data fuels collaborations with tech giants like Microsoft, and executive appointments in sales and clinical affairs operationalize launches, creating a virtuous cycle that mitigates reimbursement hurdles and accelerates adoption across neurology and psychiatry.
Future Outlook & Recommendations
Looking ahead, expect intensified consolidation through AI-enhanced BCIs and non-invasive wearables, with regulatory tailwinds favoring adolescent and home-based therapies to address aging populations and treatment-resistant conditions; executives should prioritize strategic alliances with big tech for data scalability, invest in ISO-compliant manufacturing to navigate global approvals, and leverage digital biomarkers for real-world evidence generation to secure reimbursement—recommend piloting hybrid neurotech platforms that integrate EEG wearables with cloud AI, positioning firms to lead in precision neurorehabilitation amid a 25% CAGR in the coming decade.
Final Word
Neurotechnology's convergence of capital, clearance, and collaboration heralds an era of transformative brain health equity—seize the momentum to redefine neurological care.
© 2025 Carter Sciences. All rights reserved.
This newsletter is compiled for professionals in the Neurotechnology industry.
